Dapagliflozin and Metformin Versus Sitagliptin and Metformin: A Battle for Better Glycemic Control in Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.61919/0y5w4h95Keywords:
Type 2 diabetes mellitus, dapagliflozin, sitagliptin, metformin, HbA1c, glycemic control, weight reduction, SGLT2 inhibitor, DPP4 inhibitorAbstract
Background: Type 2 diabetes mellitus (T2DM) is a globally prevalent metabolic disorder requiring combination therapies for optimal glycemic control. Among oral agents, dapagliflozin and sitagliptin are commonly used as add-on treatments to metformin, but comparative efficacy data in South Asian populations remain limited. Objective: To compare the efficacy of dapagliflozin versus sitagliptin when combined with metformin in achieving glycemic control and weight reduction in patients with T2DM. Methods: In this randomized clinical trial, 60 adult patients with uncontrolled T2DM (HbA1c >7.5%) were randomly assigned to receive either dapagliflozin 10 mg plus metformin 850 mg twice daily (Group A) or sitagliptin 100 mg plus the same metformin regimen (Group B) for 12 weeks. Primary outcomes included change in HbA1c, fasting blood glucose (FBS), postprandial blood glucose (PPBS), and weight. Target achievement of HbA1c <7% and ≥3% weight reduction were assessed. Results: Group A showed greater reductions in HbA1c (−1.40% vs −0.91%, p<0.001), FBS (−28.00 vs −20.83 mg/dL, p=0.032), PPBS (−70.93 vs −53.83 mg/dL, p=0.029), and weight (−2.85 vs −2.11 kg, p=0.041). More patients in Group A achieved HbA1c <7% (76.7% vs 50%, p=0.032) and ≥3% weight loss (80% vs 50%, p=0.015). Conclusion: Dapagliflozin combined with metformin is more effective than sitagliptin-metformin therapy in improving glycemic parameters and reducing weight over 12 weeks in T2DM patients.
References
1. American Diabetes Association. Standards of Medical Care in Diabetes—2021 Abridged for Primary Care Providers. Clin Diabetes. 2021;39(1):cd21as01.
2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045. Diabetes Res Clin Pract. 2019;157:107843.
3. Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019;79(10):1135–46.
4. Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol (Lausanne). 2019;10:80.
5. Godinho R, Mega C, Teixeira-de-Lemos E, Carvalho E, Teixeira F, Fernandes R, et al. The place of DPP-4 inhibitors in type 2 diabetes therapeutics: A “me too” or “the special one” antidiabetic class? J Diabetes Res. 2015;2015:1–28.
6. Abdullah F, Sattar A, Shaukat K, Ahmad S, Nawaz S, Maryam B. To compare the efficacy of dapagliflozin & metformin vs sitagliptin & metformin in newly diagnosed type 2 diabetic patients. Pak J Med Health Sci. 2021;15(1):85.
7. Kang BK, An SH, Kim JY, Gwak HS. Comparisons of efficacy between dapagliflozin and sitagliptin in combination with metformin in type 2 diabetes mellitus patients. Korean J Clin Pharm. 2017;27(2):99–104.
8. Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M, et al. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovasc Diabetol. 2020;19(1):1–11.
9. Raji A, Xu ZJ, Lam RLH, O’Neill EA, Kaufman KD, Engel SS. Efficacy and safety of sitagliptin compared with dapagliflozin in people ≥65 years old with type 2 diabetes and mild renal insufficiency. Diabetes Ther. 2020;11(10):2419–28.
10. Bin Rakhis SA, AlDuwayhis NM, Aleid N, AlBarrak AN, Aloraini AA. Glycemic control for type 2 diabetes mellitus patients: a systematic review. Cureus. 2022;14(6):e25988.
11. Dandona P, Mathieu C, Phillip M, Hansen L, Tschöpe D, Thorén F, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-week study. Diabetes Care. 2018;41(12):2552–9.
12. Nagao M, Sasaki J, Sugihara H, Tanimura-Inagaki K, Harada T, Sakuma I, et al. Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study. Sci Rep. 2023;13(1):134.
13. Sahay RK, Giri R, Shembalkar JV, Gupta SK, Mohan B, Kurmi P, et al. Fixed-dose combination of dapagliflozin + sitagliptin + metformin in patients with type 2 diabetes poorly controlled with metformin: Phase 3, randomized comparison with dual combinations. Adv Ther. 2023;40(7):3227–46.
14. Scott R, Morgan J, Zimmer Z, Lam RLH, O’Neill EA, Kaufman KD, et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab. 2018;20(12):2876–84.
15. Scheen AJ. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review. Diabetes Metab. 2020;46(3):186–96.
16. Mishriky BM, Tanenberg RJ, Sewell KA, Cummings DM. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2018;44(2):112–20.
17. Goldenberg RM. Choosing DPP-4 inhibitors, SGLT2 inhibitors, or both, as add-ons to metformin: Patient baseline characteristics are crucial. Clin Ther. 2017;39(12):2438–47.
18. Khan MA, Hashim MJ, King J, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes – Global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–11.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Niaz Ahmad, Muhammad Zafar Majeed Babar, Muhammad Shiraz Niaz, Hafiz Haseeb Ahsan, Sarwar Rafique, Atif Ikram, Safia Niaz (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
